Company Overview of NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a drug discovery company, engages in the identification and development of transformational biologics for the treatment of diabetes, obesity, muscle wasting, and other cardio metabolic diseases. It focuses on mining the complex biological interactions within the neuroendocrine gastrointestinal (GI) environment to elucidate the roles of previously unidentified or unexplored hormones, receptors, and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases. The company also develops novel therapeutics to modulate beta-cell regeneration for the treatment of Type 1 and Type 2 diabetes. In ad...
630 Gateway Boulevard
South San Francisco, CA 94080-7014
Founded in 2007
Key Executives for NGM Biopharmaceuticals, Inc.
Chief Executive Officer and Director
Chief Medical Officer and Vice President
Vice President of Business Development
Compensation as of Fiscal Year 2014.
NGM Biopharmaceuticals, Inc. Key Developments
NGM Biopharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 09:00 AM
Jan 7 15
NGM Biopharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 09:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Jeff Jonker, President.
NGM Biopharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:00 AM
Jul 24 14
NGM Biopharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:00 AM. Venue: Le Parker Meridien, New York, New York, United States.
MedImmune and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Jun 17 13
AstraZeneca announced that MedImmune and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1. EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis. NGM has established a proprietary platform capable of isolating and analysing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases. MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialisation of compounds resulting from the collaboration. Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration. If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|